EUVIMEDObjevte EUVIMED
Crossref

Elucidation of the mechanisms and molecular targets of KeChuanLiuWei‐Mixture for treatment of severe asthma based on network pharmacology

Yanqi Cheng, Ding Sun, Lu Zou, Shaobin Li, Ling Tang, Xiao Yu, Binqing Tang, Yingen Wu iD, Hong Fang iD

Chemical Biology & Drug Design · 2023

DOI: 10.1111/cbdd.14302 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2023. Written by Yanqi Cheng and 8 co-authors. Institution: Prevention and Health Care Department of TCM, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Major MEDLINE topics: Asthma, Network Pharmacology, Drugs, Chinese Herbal. Cited 1 times so far (Crossref); 34 references. Funded by: Longhua Medical Scholar, "Shanghai Science and Technology Innovation Action Plan" Medical Innovation Research Special Project.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

KeChuanLiuWei‐Mixture (KCLW) is widely used as a Chinese medicine prescription to treat severe asthma. However, the underlying therapeutic mechanism of KCLW remains unclear. In this study, a network pharmacology method was used to identify the chemical constituents of KCLW by the TCMSP database and ultra‐performance liquid chromatography coupled with time‐of‐flight mass spectrometry. Differential expression identification, protein–protein interaction (PPI) network and functional enrichment analysis were used to screen key targets of KCLW for severe asthma. Our results confirmed that quercetin, luteolin, kaempferol, and wogonin are the most critical active ingredients in KCLW. Moreover, the 16 relevant severe asthma‐related targets of KCLW were obtained by overlapping the PPI networks of the KCLW putative targets and severe asthma‐related genes, among which the most important targets were IL‐6, NOS2, VEGFA, CXCL2, and PLAT. Functionally, the 16‐targets and their interacting differentially expressed genes were primarily related to biological functions and pathways related to immunity and inflammation, such as inflammatory response, T cell differentiation, Nrf2/HO‐1 signaling pathway, TGF‐β/Smad signaling pathway, and NF‐κB signaling pathway. KCLW inhibited inflammation in PDGF‐BB‐induced airway smooth muscle cells. In summary, this study demonstrates the active substance and potential therapeutic mechanism of KCLW in severe asthma, and offers a clinical direction for KCLW against severe asthma.

Subjects

MeSH terms (MEDLINE)

AsthmaNetwork PharmacologyDrugs, Chinese HerbalHumansProtein Interaction MapsKaempferolsQuercetinLuteolinSignal TransductionFlavanonesChromatography, High Pressure LiquidAnti-Asthmatic Agents

Author keywords

KeChuanLiuWei-Mixturemass spectrometrynetwork pharmacologysevere asthmatraditional Chinese medicine

Substances

Drugs, Chinese HerbalKaempferolskaempferolwogoninQuercetinLuteolinFlavanonesAnti-Asthmatic Agents

Authors and institutions

  • Prevention and Health Care Department of TCM, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Teaching and Practising Center, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Respiratory Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

ORCID profiles: Yingen Wu, Hong Fang

Funding

  • Longhua Medical Scholar
  • "Shanghai Science and Technology Innovation Action Plan" Medical Innovation Research Special Project

Cite

APA

Cheng, Y., Sun, D., Zou, L., Li, S., Tang, L., Yu, X., Tang, B., Wu, Y., & Fang, H. (2023). Elucidation of the mechanisms and molecular targets of KeChuanLiuWei‐Mixture for treatment of severe asthma based on network pharmacology. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14302

Vancouver

Cheng Y, Sun D, Zou L, Li S, Tang L, Yu X, et al. Elucidation of the mechanisms and molecular targets of KeChuanLiuWei‐Mixture for treatment of severe asthma based on network pharmacology. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14302

BibTeX
@article{Cheng2023,
  author = {Cheng, Yanqi and Sun, Ding and Zou, Lu and Li, Shaobin and Tang, Ling and Yu, Xiao and Tang, Binqing and Wu, Yingen and Fang, Hong},
  title = {Elucidation of the mechanisms and molecular targets of KeChuanLiuWei‐Mixture for treatment of severe asthma based on network pharmacology},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  doi = {10.1111/cbdd.14302}
}
Start for free →